L3VLUP
ProSign in

XRAY · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

XRAYLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • XRAY
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterXRAYLLY
Q3 202014 holders, $2.3bn33 holders, $14.1bn
Q4 202011 holders, $2.7bn29 holders, $17.3bn
Q1 202116 holders, $3.7bn24 holders, $23.0bn
Q2 202123 holders, $3.8bn24 holders, $27.8bn
Q3 202118 holders, $3.3bn31 holders, $29.9bn
Q4 202113 holders, $2.8bn31 holders, $34.7bn
Q1 202216 holders, $2.8bn24 holders, $35.3bn
Q2 202218 holders, $2.0bn33 holders, $42.7bn
Q3 202217 holders, $1.5bn31 holders, $43.4bn
Q4 202214 holders, $1.6bn31 holders, $46.6bn
Q1 202311 holders, $2.2bn33 holders, $44.3bn
Q2 202310 holders, $1.9bn37 holders, $59.6bn
Q3 202315 holders, $1.7bn44 holders, $67.6bn
Q4 202313 holders, $1.7bn45 holders, $73.6bn
Q1 202412 holders, $1.1bn41 holders, $95.3bn
Q2 20249 holders, $781m43 holders, $110bn
Q3 20248 holders, $941m45 holders, $107bn
Q4 20249 holders, $648m46 holders, $93.9bn
Q1 20259 holders, $586m42 holders, $98.4bn
Q2 20258 holders, $639m43 holders, $93.2bn
Q3 20256 holders, $369m39 holders, $86.7bn
Q4 20255 holders, $199m41 holders, $123bn
Q1 20267 holders, $273m39 holders, $106bn
Q2 20265 holders, $61m44 holders, $132bn
XRAY

Dentsply Sirona Inc

Holders
6
Reported value
$369m
Buyers
4
Sellers
2

Breadth +2 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only XRAY (4)

ARK Investment Management LLC, First Eagle Investment Management LLC, Moore Capital Management LP, Voloridge Investment Management LLC

Only LLY (37)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, and 12 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →